Cargando…

Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer

BACKGROUND: Limited real-world data exist regarding the efficacy of palbociclib in combination with endocrine therapy in pre/perimenopausal women with metastatic breast cancer. OBJECTIVE: We aimed to compare real-world tumor responses among pre/perimenopausal women who initiated palbociclib plus an...

Descripción completa

Detalles Bibliográficos
Autores principales:	DeMichele, Angela, Robert, Nicholas, Chen, Connie, Kim, Sindy, Zhang, Zhe, Lu, Dongrui Ray, Aguilar, Kathleen M., Wang, Yunfei, Li, Benjamin, Schneeweiss, Sebastian, Rassen, Jeremy A., Gaffney, Michael, McRoy, Lynn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345062/ https://www.ncbi.nlm.nih.gov/pubmed/37428347 http://dx.doi.org/10.1007/s11523-023-00979-1

Ejemplares similares

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer
por: Rugo, Hope S, et al.
Publicado: (2023)

Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older
por: Brufsky, Adam, et al.
Publicado: (2023)

Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice
por: Brufsky, Adam, et al.
Publicado: (2023)

Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
por: Brufsky, Adam, et al.
Publicado: (2021)

Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2023)

Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice
por: DeMichele, Angela, et al.
Publicado: (2021)

Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer
por: Huang, Weiwei, et al.
Publicado: (2020)

Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis
por: Brufsky, Adam, et al.
Publicado: (2022)

Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
por: Dackus, Gwen M H E, et al.
Publicado: (2021)

P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer—A Podcast
por: Brufsky, Adam, et al.
Publicado: (2023)

Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network
por: Law, Jeanna Wallenta, et al.
Publicado: (2022)

Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval
por: Kish, J. K., et al.
Publicado: (2018)

Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
por: Turner, Nicholas C., et al.
Publicado: (2019)

Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer
por: Gelmon, Karen A., et al.
Publicado: (2019)

Profile of palbociclib in the treatment of metastatic breast cancer
por: Ehab, Moataz, et al.
Publicado: (2016)

Palbociclib Plus Letrozole for the Treatment of Metastatic Breast Cancer: An Illustrative Case Scenario
por: Orbaugh,1, Kristi, et al.
Publicado: (2016)

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)
por: Finn, Richard S., et al.
Publicado: (2020)

Effectiveness of palbociclib with aromatase inhibitors for the treatment of advanced breast cancer in an exposure retrospective cohort study: implications for clinical practice
por: Alves da Costa, Filipa, et al.
Publicado: (2023)

Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2
por: Gelmon, Karen, et al.
Publicado: (2021)

Early treatment-related neutropenia predicts response to palbociclib
por: McAndrew, Nicholas P., et al.
Publicado: (2020)

Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia
por: Sun, James, et al.
Publicado: (2021)

Aromatase inhibitor strategies in metastatic breast cancer
por: McArthur, Heather L, et al.
Publicado: (2010)

Palbociclib in metastatic breast cancer: current evidence and real-life data
por: Serra, Francesco, et al.
Publicado: (2019)

Progesterone for Symptomatic Perimenopause Treatment – Progesterone politics, physiology and potential for perimenopause
por: Prior, J.C.
Publicado: (2011)

PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant
por: Degenhardt, Tom, et al.
Publicado: (2023)

Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India
por: Loi, Sherene, et al.
Publicado: (2021)

Perimenopausal and Postmenopausal Health
por: Cheung, Angela M, et al.
Publicado: (2004)

Migraine during perimenopause
por: Battista Allais, Giovanni, et al.
Publicado: (2015)

Don’t ignore perimenopause
por: Prior, Jerilynn C., et al.
Publicado: (2023)

A Metastatic Invasive Mole in a Perimenopausal Woman: A Rare Case
por: Tomé, Ana I, et al.
Publicado: (2023)

Perimenopausal syndrome and mood disorders in perimenopause: prevalence, severity, relationships, and risk factors
por: Li, Rui-xia, et al.
Publicado: (2016)

Real-World Clinical Data of Palbociclib in Asian Metastatic Breast Cancer Patients: Experiences from Eight Institutions
por: Lee, Jieun, et al.
Publicado: (2021)

The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer
por: Fu, Fulbert, et al.
Publicado: (2022)

Population Pharmacokinetics of Palbociclib in a Real-World Situation
por: Royer, Bernard, et al.
Publicado: (2021)

Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
por: Zhu, Zhou, et al.
Publicado: (2022)

Fatal Statin-Induced Rhabdomyolysis by Possible Interaction with Palbociclib
por: Nelson, Kellie Lynn, et al.
Publicado: (2017)

Measuring prevalence and incidence of chronic conditions in claims and electronic health record databases
por: Rassen, Jeremy A, et al.
Publicado: (2018)

The Swiss Perimenopause Study – study protocol of a longitudinal prospective study in perimenopausal women
por: Willi, Jasmine, et al.
Publicado: (2020)

Steroid Hormone Secretion Over the Course of the Perimenopause: Findings From the Swiss Perimenopause Study
por: Grub, Jessica, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_70e2krqhhls4letgio7u94eqvf